S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.31 (+0.89%)
AAPL   142.96 (+2.80%)
MSFT   229.60 (+1.62%)
FB   278.09 (+1.31%)
GOOGL   1,895.60 (+0.16%)
AMZN   3,291.25 (-0.03%)
TSLA   881.44 (+4.11%)
NVDA   546.50 (-0.36%)
BABA   261.20 (+1.00%)
CGC   32.73 (-3.17%)
GE   10.97 (-1.26%)
MU   81.27 (-1.23%)
AMD   94.25 (+1.57%)
NIO   59.98 (-3.18%)
T   29.06 (+0.45%)
F   11.29 (-2.00%)
ACB   10.18 (-4.41%)
BA   203.41 (-1.18%)
DIS   171.72 (-0.61%)
NFLX   556.93 (-1.46%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.31 (+0.89%)
AAPL   142.96 (+2.80%)
MSFT   229.60 (+1.62%)
FB   278.09 (+1.31%)
GOOGL   1,895.60 (+0.16%)
AMZN   3,291.25 (-0.03%)
TSLA   881.44 (+4.11%)
NVDA   546.50 (-0.36%)
BABA   261.20 (+1.00%)
CGC   32.73 (-3.17%)
GE   10.97 (-1.26%)
MU   81.27 (-1.23%)
AMD   94.25 (+1.57%)
NIO   59.98 (-3.18%)
T   29.06 (+0.45%)
F   11.29 (-2.00%)
ACB   10.18 (-4.41%)
BA   203.41 (-1.18%)
DIS   171.72 (-0.61%)
NFLX   556.93 (-1.46%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.31 (+0.89%)
AAPL   142.96 (+2.80%)
MSFT   229.60 (+1.62%)
FB   278.09 (+1.31%)
GOOGL   1,895.60 (+0.16%)
AMZN   3,291.25 (-0.03%)
TSLA   881.44 (+4.11%)
NVDA   546.50 (-0.36%)
BABA   261.20 (+1.00%)
CGC   32.73 (-3.17%)
GE   10.97 (-1.26%)
MU   81.27 (-1.23%)
AMD   94.25 (+1.57%)
NIO   59.98 (-3.18%)
T   29.06 (+0.45%)
F   11.29 (-2.00%)
ACB   10.18 (-4.41%)
BA   203.41 (-1.18%)
DIS   171.72 (-0.61%)
NFLX   556.93 (-1.46%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.31 (+0.89%)
AAPL   142.96 (+2.80%)
MSFT   229.60 (+1.62%)
FB   278.09 (+1.31%)
GOOGL   1,895.60 (+0.16%)
AMZN   3,291.25 (-0.03%)
TSLA   881.44 (+4.11%)
NVDA   546.50 (-0.36%)
BABA   261.20 (+1.00%)
CGC   32.73 (-3.17%)
GE   10.97 (-1.26%)
MU   81.27 (-1.23%)
AMD   94.25 (+1.57%)
NIO   59.98 (-3.18%)
T   29.06 (+0.45%)
F   11.29 (-2.00%)
ACB   10.18 (-4.41%)
BA   203.41 (-1.18%)
DIS   171.72 (-0.61%)
NFLX   556.93 (-1.46%)
GILD   68.16 (+1.82%)
Log in
NASDAQ:VRTX

Vertex Pharmaceuticals Stock Forecast, Price & News

$241.31
+3.72 (+1.57 %)
(As of 01/25/2021 03:59 PM ET)
Add
Compare
Today's Range
$239.10
Now: $241.31
$242.94
50-Day Range
$224.04
MA: $231.52
$238.64
52-Week Range
$197.47
Now: $241.31
$306.08
Volume84,027 shs
Average Volume1.69 million shs
Market Capitalization$62.75 billion
P/E Ratio30.47
Dividend YieldN/A
Beta0.79
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals logo

MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

11th out of 1,922 stocks

Pharmaceutical Preparations Industry

5th out of 771 stocks

Analyst Opinion: 3.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VRTX
CUSIP92532F10
Phone617-341-6100
Employees3,000
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.16 billion
Cash Flow$5.22 per share
Book Value$23.66 per share

Profitability

Net Income$1.18 billion

Miscellaneous

Market Cap$62.75 billion
Next Earnings Date2/1/2021 (Confirmed)
OptionableOptionable
$241.31
+3.72 (+1.57 %)
(As of 01/25/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

How has Vertex Pharmaceuticals' stock price been impacted by COVID-19?

Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VRTX stock has increased by 9.7% and is now trading at $241.80.
View which stocks have been most impacted by COVID-19
.

Is Vertex Pharmaceuticals a buy right now?

30 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 6 hold ratings, 23 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vertex Pharmaceuticals stock.
View analyst ratings for Vertex Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Vertex Pharmaceuticals?

Wall Street analysts have given Vertex Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vertex Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among Vertex Pharmaceuticals' employees.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, February 1st 2021.
View our earnings forecast for Vertex Pharmaceuticals
.

How can I listen to Vertex Pharmaceuticals' earnings call?

Vertex Pharmaceuticals will be holding an earnings conference call on Monday, February 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its earnings results on Thursday, October, 29th. The pharmaceutical company reported $2.64 earnings per share for the quarter, topping analysts' consensus estimates of $1.96 by $0.68. The pharmaceutical company earned $1.54 billion during the quarter, compared to analyst estimates of $1.48 billion. Vertex Pharmaceuticals had a trailing twelve-month return on equity of 28.55% and a net margin of 38.51%. Vertex Pharmaceuticals's quarterly revenue was up 61.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.23 EPS.
View Vertex Pharmaceuticals' earnings history
.

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals declared that its Board of Directors has authorized a stock buyback program on Wednesday, July 31st 2019, which permits the company to repurchase $500,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's board believes its stock is undervalued.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Thursday, October, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $6-6.2 billion, compared to the consensus revenue estimate of $6.02 billion.

What price target have analysts set for VRTX?

30 brokerages have issued 12 month price objectives for Vertex Pharmaceuticals' stock. Their forecasts range from $230.00 to $340.00. On average, they expect Vertex Pharmaceuticals' share price to reach $289.72 in the next year. This suggests a possible upside of 19.8% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Are investors shorting Vertex Pharmaceuticals?

Vertex Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totaling 3,250,000 shares, an increase of 21.3% from the December 15th total of 2,680,000 shares. Based on an average daily volume of 2,110,000 shares, the short-interest ratio is presently 1.5 days.
View Vertex Pharmaceuticals' Short Interest
.

Who are some of Vertex Pharmaceuticals' key competitors?

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), salesforce.com (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the following people:
  • Dr. Jeffrey Marc Leiden, Exec. Chairman (Age 65, Pay $4.88M)
  • Dr. Reshma Kewalramani, CEO, Pres & Director (Age 48, Pay $2.03M)
  • Mr. Charles F. Wagner Jr., Exec. VP & CFO (Age 53, Pay $1.66M)
  • Mr. Amit K. Sachdev, Exec. VP & Chief Patient Officer (Age 53, Pay $1.41M)
  • Mr. Stuart A. Arbuckle, Exec. VP & Chief Commercial Officer (Age 55, Pay $2.07M)
  • Mr. Paul M. Silva, Sr. VP & Corp. Controller (Age 55, Pay $833.97k)
  • Dr. David M. Altshuler, Exec. VP of Global Research & Chief Scientific Officer (Age 56)
  • Mr. Mike Tirozzi, SVP and Chief Information & Data Officer
  • Mr. Michael J. Parini, Exec. VP & Chief Admin., Legal and Bus. Devel. Officer (Age 46)
  • Mr. Michael Partridge, Sr. VP of Investor Relations

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.30%), Manning & Napier Group LLC (0.15%), New York State Teachers Retirement System (0.14%), Welch & Forbes LLC (0.07%), Peregrine Capital Management LLC (0.06%) and Strs Ohio (0.05%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals
.

Which major investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Pacer Advisors Inc., Chesley Taft & Associates LLC, State of Alaska Department of Revenue, Lederer & Associates Investment Counsel CA, Cypress Capital Group, Gateway Investment Advisers LLC, and Vigilant Capital Management LLC. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, and Yuchun Lee.
View insider buying and selling activity for Vertex Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Vertex Pharmaceuticals stock?

VRTX stock was purchased by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Candriam Luxembourg S.C.A., LVM Capital Management Ltd. MI, Peregrine Capital Management LLC, Louisiana State Employees Retirement System, Consolidated Investment Group LLC, Transform Wealth LLC, and Welch & Forbes LLC.
View insider buying and selling activity for Vertex Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $241.80.

How big of a company is Vertex Pharmaceuticals?

Vertex Pharmaceuticals has a market capitalization of $62.88 billion and generates $4.16 billion in revenue each year. The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. Vertex Pharmaceuticals employs 3,000 workers across the globe.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is www.vrtx.com.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.